Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HUC-MSC in Type 2 Diabetic Nephropathy
NCT04216849Phase 2Unknown
- Sponsor
- Shanghai East Hospital
- Start
- Jul 2020
- Primary completion
- Feb 2022
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of human umbilical cord mesenchymal stem cells in diabetic nephropathy (DN) (2 arms), sponsored by Shanghai East Hospital. Primary endpoints: Urinary Albumin Creatinine Ratio at 48 weeks and Estimated Glomerular Filtration Rate at 48 weeks. Status: unknown.
02
Drugs
human umbilical cord mesenchymal stem cells
03
Conditions
diabetic nephropathy (DN)
Beyond the preview
Go deeper on NCT04216849.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04216849.